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ABSTRACT 
Objective: Successful treatment of glioma still remains a tough challenge. The present study aims at the development and evaluation of carmustine 
loaded nanosize phospholipid vesicles (CNLVs) for the treatment of glioma.  
Methods: The experimental NLVs were developed by conventional lipid layer hydration technique and were characterized by different in vitro tools 
such as diffraction light scattering (DLS), zeta potential, field emission scanning electron microscopy (FESEM), cryo-transmission electron 
microscopy (cryo-TEM), in vitro drug loading capacity, drug release study etc. In vitro cytotoxicity and cellular uptake of the optimized drug-loaded 
NLVs were carried out in U87MG human glioblastoma cell line. In vivo pharmacokinetic study was conducted in Swiss albino mice.  
Results: DLS data showed an average vesicle diameter of 92 nm with narrow size distribution. Optimized CNLVs were spherical in shape with a smooth 
surface as depicted from FESEM data. Cryo-TEM study confirmed formation of unilamellar vesicles with intact outer bilayer. A reasonable drug loading of 7.8 
% was reported for the optimized CNLVs along with a sustained release of CS over a 48 h study period. In vitro cytotoxicity assay revealed a considerable 
higher toxicity of CNLVs than free drugs in the U87MG cells. Confocal microscopy showed a satisfactory internalization of the optimized drug-loaded NLVs in 
the tested cell line. Pharmacokinetic data demonstrated an enhanced mean residence time of optimized CNLVs in blood than free drug.  
Conclusion: Results depicted the potential of experimental CNLVs for the treatment of glioma after further in vivo tests. 
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INTRODUCTION 
Successful treatment of brain tumor still remains a herculean task 
for medical experts. Glioma is the most common type of primary 
brain tumor that develops in the glial cells of the brain [1]. Based on 
the type of glial cells, gliomas can be of astrocytomas, ependymomas, 
oligodendrogliomas etc. [1]. Glioma at its fourth stage is referred to 
as glioblastoma multiforme, which is the most dangerous stage with 
a median survival rate of 1-2 y. According to a report from the 
American Cancer Society, an estimated 23,890 adults in the United 
States have been diagnosed with primary brain tumor in the year 
2019-20, along with about 3,540 children under the age of 15, which 
simply exposes the inefficiency of the present therapy [2]. The 
delicate and sensitive characteristics of brain tissue make surgery 
and radiotherapy very limited, whereas the presence of the blood-
brain barrier (BBB) further restricts the usefulness of chemotherapy 
[3]. Many conventional chemotherapeutics drugs are though 
available in the market, but the majority of them fails to maintain the 
desired therapeutic concentration in the brain tissue due to their 
inability to pass effectively through BBB [4]. Again, severe dose-
related toxic effects associated with conventional chemotherapy 
throw further challenges for the successful treatment of glioma. 
Novel drug delivery strategies like nanoliposomes, nanoparticles, 
polymeric micelles etc. have been investigated widely in past years 
to improve the efficacy of conventional chemotherapeutic agents [5-
7]. However, till today, very few of them are available at the clinical 
stage. Among various types of nanocarrier platforms, nanosize lipid 
based vesicular carriers (NLVs) have been largely preferred for the 
successful delivery of toxic chemotherapeutic drugs to the brain [8]. 
Due to high lipophilic nature as well as ultra-small size, they fulfill 
the prime requisite criteria to overcome BBB to get into the brain. 
NLVs, also referred as nanoliposomes, are the ultra-micron size 
phospholipid vesicles consisting of self-assembled lipid bilayers 
enclosing small aqueous phase in their core [9]. Due to this unique 
feature, they act as dual platforms for both hydrophobic and 
hydrophilic molecules. The hydrophobic/lipophilic agents get 
entrapped in the outer lipid bilayer, where as the hydrophilic agents 
remain encapsulated in the aqueous core [9]. NLVs owing to their 
biodegradability, biocompatibility, sustained drug release property, 
non-immunogenicity, ease of surface manipulation etc. have been 
the preferred drug delivery vehicle in nanomedicine based research 
[10]. Due to sustained delivery of the loaded cargo as well as site-
specific delivery, the dose of the cytotoxic anticancer drugs is 
expected to be reduced, leading to better treatment outcomes and 
fewer side effects.  
Carmustine (CS) is a cell-cycle phase nonspecific alkylating 
anticancer drug, which has been used in the treatment of brain 
tumors and other types of malignancies [11]. It causes cross-linking 
in the nucleic acids, leading to inhibition of protein synthesis. 
However, its short half-life and serious toxic effects like pulmonary 
fibrosis, bone marrow depression etc. limits its effective use in the 
treatment of glioma [11-13]. Thus, there is a need to develop novel 
strategies for the effective delivery of CS to the brain and thereby 
reducing the dose-related side effects associated with the 
conventional forms. Till now, no phospholipid based nanocarriers 
have been evaluated for the successful delivery of CS for the 
treatment of glioma. 
In the lieu of this, the present study aims to investigate the 
anticancer potential of phospholipid based nanovesicular carrier 
systems loaded with CS for glioma therapy. The NLVs will be 
prepared by the conventional method with optimization of critical 
manufacturing conditions to achieve the desired size range. 
Preferably, we want to develop the formulation within 100 nm size 
range for effective tumor tissue permeation and retention as well as 
to escape from reticuloendothelial system. The selected drug-loaded 
NLVs will be tested for their in vitro effectiveness in U87MG human 
glioblastoma cell line. Further, in vivo pharmacokinetic (PK) study 
will also be carried out in experimental animal models, which is yet 
to be reported.  
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MATERIALS AND METHODS 
Materials 
CS was obtained as a gift sample from Fresenius-Kabi Oncology Ltd. 
(West Bengal, India). Cholesterol (CHL), soya-L-α-lecithin (SL), 1,2-
distearoyl-sn-glycero-3-phosphotidylethanolamine (DSPE) were 
procured from Merck (Mumbai, India). Chloroform, butylated hydroxyl 
anisole (BHA), fluorescein isothiocyanate (FITC) were purchased from 
HiMedia Laboratories Pvt. Ltd (Mumbai, India). 4ꞌ,6-Diamidino-2-
phenylindole) (DAPI) and tetrazolium dye 3-(4,5-dimers 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were 
purchased from Sigma-Aldrich (Banglore, India). U87MG human glioma 
cells were procured from National Center for Cell Science (Pune, India). 
All other chemicals used in the experiment were of analytical grade. 
Animals 
For PK studies, healthy Swiss albino mice of either sex (male: female 
ratio 1:1) were used. Animals were purchased from Indian Institute 
of Chemical Biology (IICB), Kolkata. All animal-related experiments 
were in accordance with CPSCEA guidelines. Animals were kept in 
polypropylene cages and maintained in the Jadavpur university 
animal house at normal room temperature, 55 % relative humidity 
environment with normal day and night cycle. The protocol of the 
animal study was approved by the Institutional Animal Ethical 
Committee, protocol number: SVCP/IAEC/Ph. d/02/2017. Before 
experiments, animals were properly fed standard diet and drinking 
water ad libitum. The guidelines of Animal Ethical Committee, 
Jadavpur University were followed strictly during the entire study 
period. The animals were kept for three weeks in the animal house 
environment before the study. 
Method of development of experimental NLVs 
The experimental drug-loaded NLVs were prepared by a conventional 
thin-film hydration method with necessary modification of process 
parameters [14]. For the preparation of CS loaded NLVs (CNLVs), SL was 
used as the main phospholipid. Along with that, we used DSPE and CHL. 
Briefly, weighed amount of CS, SL, CHL along with DSPE were dissolved 
in a required volume of chloroform taken in a 250 ml round bottom 
flask. To this mixture, BHA (2 % w/v) was added as an antioxidant, since 
all phospholipids are generally sensitive to oxidation. The prepared 
mixture was then subjected to gentle rotation along with the 
evaporation of the solvent in a rotary vacuum evaporator (Rotavap, 
PBU-6, Superfit, Mumbai, India), connected with a water bath. The 
temperature of the water bath was kept at 40 °C. After, evaporation of 
chloroform, a thin film was formed along the inner wall of the round 
bottom flask. The flask was then kept in a dessicator overnight, which 
caused further removal of any residues of organic solvent still left in the 
thin film. On day 2, the formed thin film was hydrated with phosphate 
buffer saline (PBS), pH 7.4 for 1 h at a rotation of 130 rpm. During this 
period, the formed film was completely dispersed in the PBS. Following 
hydration, the mixture was subjected to sonication in a bath-type 
sonicator (Trans-o-sonic, Mumbai, India). Sonication helps the reduction 
of large size vesicles into the desired ultra-small size range. After 
sonication, the formulation was allowed to stand for 1 h at room 
temperature followed by storage in a refrigerator overnight at 4 °C. On 
day 3, the sample was subjected to cold centrifugation at 15 000 rpm for 
45 min (Sigma Lab Centrifuge, UK). After centrifugation, the supernatant 
was discarded and the sediments were collected, which was stored at-20 
°C overnight. On next day, the sample was dried for 12 h in a lyophilizer 
(laboratory lyophilizer, Kolkata, India). 
Development of fluorescent NLVs  
For cellular uptake study, fluorescent CNLVs were prepared with FITC. 
For this, FITC at a concentration of 0.4 % w/v was dissolved in a 
required volume of chloroform and ethanol mixture. From this stock 
preparation, about 50 µl was added during the first step of preparation 
of CNLVs. All other steps mentioned above remained unchanged [15].  
Characterization of CS loaded NLVs 
Determination of average vesicle diameter (Z-average) and 
surface potential 
For the determination of mean vesicle diameter (Z-average), 
polydispersity index (PDI) and overall surface charge (zeta 
potential) of the experimental formulations, a weighed amount of 
the formulation was dispersed in milli Q water, sonicated for 5 min 
and observed under a dynamic light scattering (DLS) instrument 
(DLS-nano ZS, Zetasizer, Malvern Instrument Ltd, UK) [16]. The data 
was interpretated by the instrument software. 
Percentage of drug loading and loading efficiency  
For the calculation of the amount of CS loaded in the experimental 
NLVs, about 2 mg of the lyophilized formulation was dissolved in 
required volume of acetonitrile. The sample was then sonicated in a 
bath sonicator for 10 min. After that, it was vortexed for another 3 
min followed by centrifugation at 15 000 rpm. After centrifugation, 
the sediments were discarded and the absorbance of the collected 
supernatant was measured at 230 nm in UV-visible 
spectrophotometer (Advanced Microprocessor UV-Visible single 
beam, Intech 295, India) [15, 16].  
The amount of CS loaded in the experimental NLVs was calculated 
by applying the following formula 
% CS loading =  ………. (1) 
% CS loading efficiency = ……. (2) 
Yield percentage 
To determine the % yield of each formulation batch, the fully dried 
CNLVs obtained after lyophilization was weighed after each batch 
run [15]. The % yield was calculated by applying following equation. 
% Yield = … (3) 
Surface morphology study by field emission scanning electron 
microscopy (FESEM) 
To obtain surface morphology of the optimized CNLVs (CNLV-2), 
electron microscope was used (JSM 6100, JEOL, Japan). For the 
experiment, lyophilized CNLV-2 was spread on carbon tape, fixed over a 
stub. Platinum coating was applied on the tested sample for 5 min with a 
voltage of 10 kV by means of a platinum coater [14]. Finally, the samples 
were observed under FESEM under liquid nitrogen conditions. 
Cryo-transmission electron microscopy (Cryo-TEM) 
For Cryo-TEM analysis, the weighed amount of lyophilized CNLV-2 
was dispersed in Milli-Q water. The dispersion was vortexed in a 
cyclomixture for 5 min and a little quantity of the dispersed CNLV-2 
(4 µl) was taken on a clean grid. The sample was then immediately 
vitrified in liquid ethane followed by storage in liquid nitrogen 
condition until imaging [15]. Images of the sample were taken with 
the help of a electron microscope (Tecnai Polora, version 4.6, 
Netherlands) equipped with an FEI Eagle 4K x 4K charge-coupled 
device (CCD) camera. During imaging, vitreous grids were 
transferred into the electron microscope with the help of a 
cryostage. Throughout the experiment, the temperature of the 
samples was maintained at -170 °C to observe the NLVs in their 
native form without any degradation to the bilayer structure.  
In vitro drug release study 
For the in vitro drug release study of the selected formulation 
(CNLV-2), the conventional dialysis method was employed [16, 17]. 
For the experiment, a weighed amount of lyophilized CNLV-2 was 
dispersed in PBS pH 7.4 containing sodium lauryl sulfate (SLS) as a 
solubilizing agent (release medium). The dispersion was put inside a 
dialysis bag. The two ends of the dialysis bag were tied with the 
thread and the whole system was immersed in a beaker containing 
100 ml of the above release medium. After that, the beaker was 
placed on a magnetic stirrer at a rotation of 300 rpm using a 
magnetic bead. At various time intervals for 24 h, 1 ml of sample was 
withdrawn from the beaker with the simultaneous replacement of 
the fresh release medium to maintain the sink condition. The 
experiment was carried out for 24 h. The samples after collection 
were filtered with the help of membrane filter followed by 
measurement of the absorbance at 229 nm with the help of High-
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Performance Liquid Chromatography system. PBS containing SLS 
was taken as the blank during measurement. 
Estimation of drug release kinetics 
Release kinetics helps to predict the mechanism of drug release from 
the tested NLVs. For this, the data obtained from the in vitro drug 
release studies were fitted in various kinetic models. We determined 
the release pattern in five different models such as zero-order 
(cumulative amount of drug released Vs time), first-order (logarithmic 
value of cumulative amount of drug remained to be released Vs time), 
Higuchi (cumulative amount of drug released Vs square root of time), 
Korsmeyer–Peppas (logarithmic value of the cumulative amount of 
drug released Vs logarithmic value of time), Hixson–Crowell (cube 
root of percentage drug remained to be released Vs time) [18]. The 
linearity of the plots was assessed from the calculated R2 values. 
Assessment of in vitro cytotoxicity  
The cytototxic effect of the CNLV-2 was tested on U87MG human 
glioblastoma cell line and the effect was compared to that of free CS 
suspension at equivalent drug concentrations. For this, MTT assay 
was used [19]. For the experiment, the tested cell line was cultured 
in Dulbecco’s modified eagle’s medium containing 10 % fetal bovine 
serum in a 96 well culture plate and maintained inside a CO2-
incubator at 37 °C. After attaining the required density of cells in the 
plates (~5 000 cells per well), the cells were treated with varying 
concentrations of CNLV-2, free drug suspension and blank NLVs 
(without drug). As a negative control, few of the wells were treated 
with equivalent volumes of pure culture medium. After 48 h, the 
media in each well was discarded and about 100 µl of MTT solution 
(1 mg/ml) was added to each well. The plate was kept inside CO2-
incubator for another 4 h. After incubation, MTT solution was 
removed out of the well followed by addition of dimethyl sulfoxide 
(100 µl) in each well. Addition of dimethyl sulfoxide caused 
solubilization of formazan crystals to produce a purple color. The 
intensity of the color is related to the number of viable cells after 
treatment in the well. The optical density was measured at 560 nm 
by micro plate reader (Spectra Max, Molecular Devices Corporation, 
Sunnyvale, USA). Percentage viability of the tested formulation and 
free drug suspension was evaluated by the following formula 
% Cell viability =  100 … (4) 
Assessment of internalization efficiency 
The internalization capacity of the selected fluorescent formulation 
(FITC-CNLV-2) was tested on the U87MG cells with the help of 
confocal microscopy [19]. For the experiment, the cells were seeded 
in six-well culture plates and allowed to grow on cover slips at a 
density of 104 cells per well. The volume of cell culture was taken as 
3 ml per well and incubated at 37 °C in CO2-incubator for 24 h. FITC 
CNLV-2 was then added to the culture wells at a concentration of 100 μg/ml. After 0.5 h, coverslips were carefully washed with PBS 
and the treated cells were fixed with 4 % paraformaldehyde 
solution. Following fixation, the cells were washed twice with fresh 
PBS and stained with DAPI. Coverslips were dried and mounted on 
glass slide for imaging by confocal laser scanning microscope (Andor 
Spinning Disc Confocal Microscope, Andor Technology, UK). 
PK study 
PK study was carried out on Swiss albino mice of body weight 20-25 
g. The animals were divided into three groups. Each group was 
having 6 animals. Group I animals were intravenously administered 
CS suspension (10 mg/kg body weight). Group II animals were 
intravenously administered CNLV-2, containing CS equivalent to 10 
mg/kg. Group III animals received saline (control group). For the 
study, post intravenous dosing, blood samples were collected from 
each animal at 0.5, 1, 3, 5, 8, 12, 18, 24 h intervals by heart puncture 
in pre-heparinized tubes. The blood samples were centrifuged using 
cold centrifuge at 5000 rpm for 10 min. Plasma was collected and 
stored at-40 °C till analysis. 
For the determination of CS concentration in plasma samples, a 
LCMS/MS technique was employed [20]. The LCMS/MS Agilent C18 
column was used. The mobile phase for the analysis was composed 
of acetonitrile, milli Q water along with formic acid (0.1 % v/v). The 
flow rate of mobile phase was kept as 0.4 ml/min. Sample volume 
for injection into the chromatographic column was 20 µl. The 
analyte was monitored using mass spectrometer equipped with a 
double quadruple along with an electrospray ionization interface, 
operated in a positive mode (ESI+). For the analysis, samples were 
mixed with about three-volume of methyl-tert-butyl ether. The 
mixture was then vortexed for 5 min followed by centrifugation at 
3000 rpm for 10 min. After the process, the extracted CS present in 
the supernatant was collected. The organic solvent was allowed to dry 
under nitrogen atmosphere. For LCMS/MS analysis, the dried samples 
were solubilized in 100 ml of the mobile phase. From the prepared 
stock, about 50 ml of reference standard solution was added in each 
sample. From the mixture, 20 µl sample was injected into the 
LCMS/MS column (Agilent 6410, Triple Quad MS-MS, USA). The 
important PK parameters i.e. area under the curve (AUC), area under 
the first moment curve (AUMC), the volume of distribution (Vd), mean 
residence time (MRT), total body clearance (Clt) etc. were determined 
using non-compartmental PK Solver software (Version 2.0)  
Statistical analysis 
All the experiments were carried out triplicate for accuracy and 
reproducibility. Data was expressed as the mean±standard deviation 
(SD). One-way ANOVA was used to evaluate statistical followed by 
Tukey post hoc test with the help of Origin Pro 8 software. 
Differences were considered statistically significant when p<0.05 at 
95 % confidence level 
RESULTS 
Formulation optimization 
Several formulations were prepared by varying concentrations of 
drug and lipids along with the variation of specific manufacturing 
parameters. All the formulations were characterized by different in 
vitro techniques. Out of several formulations, here we report three 
formulations having desired properties (table 1). We basically 
compared the formulations based on their drug loading capacity, Z-
average, as well as % yield. Out of these three, based on the 
physicochemical characteristics, we finally selected CNLV-2 as the 
optimized one for further works.  
Determination of % drug loading, loading efficiency and yield 
percentage 
The % drug loading for CNLV-2 was 7.8±0.5%, whereas for CNLV-1 
and CNLV-3, the values were 3.2±1.4 % and 4.7±0.8%, respectively. 
CNLV-2 also showed higher loading efficiency and yield percentage 
(table 1). 
 
Table 1: Formulation ingredients, % yield, % drug loading and % drug loading efficiency of selected experimental formulationsb 
Formulation code SL: CHL: DSPE ratio (w/w) % yielda Practical % drug loadinga % drug loading efficiencya 
CNLV-1 100:100:10 48.3±0.2 3.2±1.4 59.8±2.1 
CNLV-2 150:50:10 73.6±1.1 7.8±0.5 86.4±1.3 
CNLV-3 165:33:10 61.5±0.4 4.7±0.8 72.3±2.4 
aData show mean±SD (n =3). bAbbreviations: CNLV, carmustine loaded nanosize lipid vesicles  
 
Determination of Z-average and surface potential 
DLS data revealed that the experimental formulations were well 
within the desired nanosize range (fig. 1). The optimized 
formulation (CNLV-2) showed an average vesicle size of 92.31±1.3 
nm (table 2). The PDI value of CNLV-2 was 0.315±0.07 and zeta 
potential was found to be-69.6 mV (fig. 2). The lower PDI value 
suggested a narrow size distribution pattern of the experimental 
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formulation. Higher negative value of zeta potential was reported for 
the optimized formulation, which indicates the formulation would 
be stable in the suspension stage due to strong repulsive force 
between the vesicles. 
 
 
Fig. 1: Average size distributions of selected carmustine-loaded nanosize lipid vesicles (CNLV-2) 
 
 
Fig. 2: Zeta potential of selected carmustine-loaded nanosize lipid vesicles (CNLV-2) 
 
Table 2: Determination of Z-average, PDI and zeta potential of the selected formulation 
Formulation code Z-average (dnm.)a PDIa Zeta potential (mV)a 
CNLV-2 92.31±1.3 0.315±0.07 -69.6 
aData show mean±SD (n =3) 
 
Surface morphology study by FESEM 
The FESEM image of the CNLV-2 was reported here, which was 
taken at 75 000 magnification scale (fig. 3a). The FESEM data 
demonstrated the smooth surface morphology of CNLV-2. All 
vesicles were found spherical in shape and within 30-40 nm size 
range. Though vesicles were found placed closely with each other, 
but there were no signs of any lumps or formation of big 
agglomerates throughout the formulation, which justifies the good 
formulation characteristics. 
Cryo-TEM study 
Cryo-TEM images showed the formation of unilamellar vesicles with 
intact lamellarity. The size of the vesicles was below 50 nm as 
depicted from the photograph (fig. 3b). This was in good agreement 
with the data obtained from FESEM study. All the vesicles were 
found distinctively spread through the sample without any damage 
to their native structure. 
 
Fig. 3a: FESEM image of optimized formulation (CNLV-2) 
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Fig. 3b: Cryo-TEM image of optimized formulation (CNLV-2) 
In vitro drug release study and analysis of drug release kinetics 
For the in vitro drug release study of the optimized formulation 
(CNLV-2), dialysis method was employed. Release study showed a 
sustained drug release pattern over a 48 h experimental time length 
(fig. 4). Initially, the drug release increased with time, but after 12 h, 
a more sustained release property was observed for the 
experimental formulation. A cumulative amount of 82.34±3.76 % CS 
was released from the formulation over the study period. To 
determine the nature of drug release from the experimental 
formulation, release data were fitted in different kinetic equations. 
From the respective graphs, corresponding R2 values were 
calculated (table 3). For CNLV-2, among all the tested models, 




Fig. 4: In vitro drug release optimized formulation (CNLV-2). Data show mean±SD (n =3) 
 
Table 3: In vitro drug release kinetics with R2 values for a selected formulation 
Kinetic model CNLV-2 
Zero Order Kinetics y = 2.620x+7.436  
R² = 0.856 
First Order Kinetics y =-0.018x+2.378 
R² = 0.933 
Koresmeyer Peppas y = 0.942x+0.434 
R2 = 0.988 
Higuchi y = 16.71x-11.65 
R² = 0.964 
Hixon Crowell Kinetics y =-0.051x+3.541 
R² = 0.893 
 
 
Fig. 5: Comparison of U87MG cell viability (%) upon treatment with optimized formulation (CNLV-2), free drug, and blank NLVs. Data 
show mean±SD (n =3) 
Satapathy et al. 
Int J App Pharm, Vol 12, Issue 5, 2020, 240-248 
245 
Assessment of in vitro cytotoxicity  
In vitro cytotoxic or anti-proliferative effect of CNLV-2 was evaluated 
in U87MG human glioblastoma cells. MTT assay results demonstrated 
a lower IC50 (inhibitory concentration causing 50% of cell death) for 
CNLV-2 as compared to free CS (fig. 5). The plot of % cell viability 
against the tested dose (µg/ml) showed that with an increase in the 
concentration of both CNLV-2 and free drug, the death rate of U87MG 
cells increased. However, CNLV-2 was found more effective (IC50 
12.4±2.1µg/ml) as compared to free CS (IC50 23.8±1.6 µg/ml) at 
equivalent drug concentration. The results further showed that blank 
NLVs (without CS) were almost non-toxic to the U87MG cell line even 
at the highest tested concentration (fig. 5). Percentage of viable cells 
treated with blank NLVs was much higher compared to free CS, CNLV-
2, justifying non-toxic nature of components used for the formulation. 
Assessment of internalization efficiency 
To estimate whether the optimized formulation possesses the 
ability to permeate into the cancer cells or not, we tested in vitro 
internalization capacity of the fluorescent optimized formulation 
(FITC-CNLV-2) in U87MG glioblastoma cells by confocal 
microscopy (fig. 6). Confocal images of the cell line clearly showed 
preferential internalization of FITC-CNLV-2 into the cells. We have 
provided two sets of images at the same time point (0.5 h), the 
second set of images were taken at higher magnification just to get 
a clear understanding of the internalization capacity. The 
fluorescent formulations are distributed throughout the 
cytoplasm. The nuclei of the cells were stained by DAPI, which 
distinctively visualized in the image and further confirmed that 
FITC-CNLV-2 could not cross the nucleus. 
 
 
Fig. 6: I. Confocal laser microscopic images of U87MG human glioblastoma cells treated with FITC-CNLV-2 (0.5 h incubation); II. Images 
were taken at higher magnification 
 
PK study 
From the study, a reasonable difference was observed in the 
important plasma PK parameters between CNLV-2 and free CS 
treatments. The results were depicted in table 4. From the graph 
between plasma drug concentration Vs time, a prolonged blood 
residence time for CNLV-2 than free CS was clearly observed. After 
12 h, the concentration of CS was not detectable. However, CS 
encapsulated in NLVs showed a much-sustained release of the drug 
and even at 24 h, a well detectable concentration (29.56 ng/ml) was 
found (fig. 7). AUC 0–∞ value was 5348.3±211.4 ng h ml-1 for free CS 
administration, whereas it was 14656.1±1328.6 ng h ml-1 for CNLV-2 
administration. Similarly, other important parameters like AUMC, 
MRT also showed preferential enhancements for CNLV-2 as 
compared to free CS injection. MRT was increased almost 4.5 fold for 
CNLV-2 treated animals (9.31 h) than the animals treated with free 
CS (2.24 h). The results thus suggest improved pharmacokinetic 
parameters of CNLV-2 as compared to the free CS. 
 
 
Fig. 7: Plasma concentration-time profiles of CS in Swiss albino mice after i. v. administration of CNLV-2 and free CS suspension (10 
mg/kg), data show mean±SD (n=6) 
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Table 4: Estimation of pharmacokinetic parameters of CS after i. v. bolus administration of free CS and CNLV-2 suspensions 
Pharmacokinetic parameters free CSa CNLV-2a 
AUC 0–∞ (ng h ml-1) 5348.3±211.4 14 656.1±1328.6* 
AUMC 0–∞ (ng h2 ml-1) 29 162.1±2322.1* 81 471.4±131.5 
Clt (L h-1) 0.008±0.121 0.004±0.023 
MRT 0–∞ (h) 2.64±0.32 8.31±0.22* 
Vd (L) 0.04±0.31 0.16±0.03 
aData show mean±SD (n=6). bAbbreviations: AUC, area under the plasma concentration-time curve; AUMC, area under the first moment curve; Clt, 
total body clearance; MRT, mean residence time; t1/2, plasma half life; Vd, apparent volume of distribution, *Data were significantly different 




The present study was intended to develop an optimized method for 
formulation of NLVs encapsulating CS, as the model anticancer drug. 
CS is a FDA approved drug used for the treatment of brain tumor, 
however, it is associated with severe side effects. Further, presence 
of BBB restricts its successful application in glioma therapy. Thus, it 
is hypothesized that phospholipid based ultra micron size carriers 
may improve the delivery of CS to glioma cells and can maintain the 
desired therapeutic concentration by enhanced permeability and 
retention effect. During formulation development, we found that 
specific composition and process parameters have a significant 
impact on the formation of nanosize NLVs and to produce desired in 
vitro properties. Initially, we varied amount of SL, CHL (at a fixed CS 
concentration) to make different batches of formulations. However, 
we decided to keep the DSPE amount fixed in each batches. DSPE 
was not the primary phospholipid for the formation of NLVs in our 
work; rather, it has been incorporated in the formulation to increase 
the enhanced permeability and retention at the brain-
microenvironment. Among different phospholipids present in brain 
and central nervous system, DSPE constitutes almost 45% of all 
lipids. Thus, presence of DSPE is expected to impart a brain tissue-
mimicking property to the formulation, which would be helpful for 
its future in vivo studies. Reports from our previously published 
work have already demonstrated the potential of DSPE in improving 
brain delivery of drug-loaded lipid nanocarriers [15].  
In the present work, percentage drug loading was initially increased 
with an increase in the amount of drug. However, beyond certain 
amounts, percentage loading was not increased proportionally with 
the amount drug. This finding was also in good agreement with the 
previous reports [14, 15]. Further, different process parameters, such 
as duration of hydration, temperature, sonication time, speed and time 
of centrifugation etc. affected the morphology, average vesicle size as 
well as drug loading capacity of the formulations. In our work, we have 
therefore standardized critical in-process parameters to obtain NLVs 
with desired physicochemical properties. At a fixed ratio of 1:5 drug: 
lipid (w/w) along with specific manufacturing parameters such as 45 
min hydration in PBS at 140 rpm, 40 min sonication in a bath type 
sonicator, 45 min ultracentrifugation at 15 000 rpm etc. the obtained 
formulation showed satisfactory characteristics in terms of % yield, % 
drug loading and loading efficiency and thus taken for further studies 
throughout the work.  
The selected formulation (CNLV-2) showed a satisfactory percentage 
of drug loading. For nanosize vesicular carriers, it has always been a 
problem to achieve higher drug loading. However, in our case, a 
reasonable drug loading of 7.8 % was reported, which may be 
attributed to the standardized formulation and in-process parameters.  
CNLV-2 had a nanosize range as depicted from DLS study with a 
narrow distribution pattern. PDI value of CNLV-2 (0.315) was much 
less than 1, which signifies a homogenous distribution of vesicles in 
the formulation. It is known that smaller size drug carriers remain 
suspended for a longer period of time as compared to larger size 
carriers, since the rate of sedimentation of suspended particles is 
mostly governed by stoke’s law. According to stoke’s law, rate of 
sedimentation of suspended particles are directly proportional to 
the diameter of the particle. Again, a higher surface charge on the 
experimental formulations (-69.6 mV) also helps them to remain 
separated from each other due to higher repulsive force between 
individual vesicles. It has been reported that zeta potential of more 
negative than -30 mV or more positive than +30 mV is taken as 
critical to form stable suspensions [15]. Thus, in our case, ultra 
micron size (below 100 nm) and a higher negative charge of selected 
formulation would help to form stable suspension. 
FESEM images demonstrated smooth surface morphology, nanosize 
range (30-40 nm) and clear homogenous nature of the as-formed 
vesicles. It was observed that size of lyophilized CNLV-2 found in the 
FESEM image was less than those detected by DLS. It is because the 
DLS method actually measures an average hydrodynamic diameter 
of the vesicles in aqueous phase. The formed vesicles while 
dispersed long time in milli Q water during sample preparation for 
DLS measurement, might swell and increased in size than their 
native form. We found similar observations in other reports also [14, 
15]. However, size of the sample observed by cryo-TEM was in good 
agreement with that of FESEM. Cryo-TEM method actually maintains 
the NLVs in their native form where they are observed under liquid 
nitrogen environment. Thus, the delicate nature of lipid vesicles is 
well maintained in cryo-TEM method than normal TEM. Cryo-TEM 
images showed intact bilayer of the vesicles without any damage to 
the native structure. We have taken experimental NLVs at a much 
diluted state so that the vesicles could be distinctively visualized. In 
FESEM, lyophilized solid samples are taken unlike Cryo-TEM, which 
shows a relatively compact arrangement of vesicles. Cryo-TEM 
clearly confirmed the satisfactory production of NLVs in the adopted 
process as well as maintenance of their internal architecture.  
In vitro drug release study was carried out at physiological pH of 
blood (i.e. pH 7.4) to simulate the in vivo environment. As the NLVs 
are intended for administration through i. v. route only, testing of 
drug release pattern in physiological pH of blood is considered the 
ideal simulated condition. The study showed a sustained release of 
CS from the selected formulation. Initially, though the amount of 
drug release was increased with time, but after 12 h, a more 
sustained release pattern was observed. The sustained release 
property of the selected formulation would favor reduction of dose, 
dosing frequency and thus would lead to sharp reduction in dose 
related toxicity during in vivo application. The pattern of drug 
release when fitted to different kinetics models, the formulation was 
best fitted with the Korsmeyer–Peppas kinetics model. It signifies 
that the drug release from CNLV-2 might follow complex mechanisms 
with involvement of both diffusion and erosion. In case of the 
Korsmeyer–Peppas model, the fraction of drug released with time is generally represented as Mt/M∞ = Ktn, where the release mechanism 
is governed by ‘n’. When n ≤ 0.45, the drug release is said to follow 
Fickian diffusion mechanism. When value of n lies in between 0.45–
0.89, the drug release is considered to follow non-Fickian. When n ≥ 
0.89, drug release is considered to follow Case II (relaxational) 
transport [19]. In our case, ‘n’ value was found as 0.793, which 
suggests that the drug release might follow non-Fickian diffusion. 
The in vitro cytotoxicity data demonstrated a higher death rate of 
U87MG cells treated with CNLV-2 as compared to free CS suspension 
at equivalent drug concentration. Data clearly revealed better 
antitumor efficacy of the tested formulation than the free drug. CS 
delivered through NLVs was more cytotoxic to the glioma cells with 
lower IC50 value (12.4 µg/ml) as compared to free CS (23.8 µg/ml). 
The blank formulation (without drug) showed no significant impact 
on the cell death rate even at the highest tested concentrations. 
Clearly, it suggests the biocompatible and non-toxic nature of 
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excipients of the formulation, which is a good sign. Higher 
cytotoxicity of the optimized formulation against U87MG cells is 
very crucial since it would favor for future in vivo applications. 
In order to visualize the internalization of CNLV-2, FITC was used as 
a fluorescent marker. The FITC-CNLV-2 produced green 
fluorescence while visualized under confocal microsope. Further, 
DAPI was used to stain nucleus, which produces blue fluorescence. 
Confocal images depicted a preferential uptake of FITC-CNLV-2 by 
U87MG cells. The formulation was predominantly spread 
throughout the cytoplasm around the nucleus. Higher cellular 
internalization of the optimized formulation could be attributed to 
the ultra micron size range. It may be possible that due to a much 
smaller size as well as higher lipophilic property, the experimental 
NLVs could sufficiently permeate through the cancer cells, which is 
again a good finding towards successful application of the 
experimental formulation for the treatment of glioma. 
The PK parameters of CNV-2 treated animals demonstrated a higher 
value of AUC, AUMC, Vd, MRT in comparison to animals treated with 
free CS suspension. The plasma drug concentration for CNLV-2 
treated group at 24 h was reasonably higher than that of CS treated 
groups. The drug concentration for free CS treated groups was not 
detectable after 12 h, since it dropped beyond the minimum 
detectable limit (10 ng/ml) of our LCMS/MS system. The data 
justifies the potential of the optimized formulation for prolonged 
blood circulation, thus more bioavailability. Owing to its extreme 
small size, the experimental NLVs might escape from the trap of 
reticuloendothelial cells successfully and maintained a longer 
presence in blood. 
Harikiran et al., 2018 prepared CS loaded lactoferrin nanoparticles 
and tested their in vitro efficacy against human glioblastoma cell line 
[21]. Zena Hasan et al., 2019 prepared HER2 antibody functionalized 
nanosphere carrier for a combined CS-busulfan and trastuzumab 
and assessed the anticancer efficacy in lung carcinoma cell line [22]. 
Zhong et al., 2012 prepared the complex of anionic liposomes and 
adenovirus and encapsulated CS as a chemotherapeutic agent. The 
formulations were tested on Lewis lung carcinoma and B16 
melanoma cells both in vitro and in vivo [23].  
However, our work will be quite different from all such reported 
works, since till now CS loaded NLVs have not been evaluated for 
their in vitro efficacy on U87MG cells. Further, no study has been 
reported so far the PK profile of CS encapsulated in NLVs. The 
formulation development steps were quite simple and optimized. 
Further all other data including FESEM, cryo-TEM, confocal 
microscopy, PK profile etc. were quite satisfactory and unique. 
CONCLUSION 
The study reported an optimized and easily controllable method for 
the development of a phospholipid based nanovesicular system for 
sustained delivery of CS for the treatment of glioma. The selected 
formulation (CNLV-2) showed a preferable nanosize (within 100 
nm) as depicted from DLS, FESEM and cryo-TEM study. A reasonable 
drug loading (7.8%) was reported for CNLV-2 along with a sustained 
drug release property in a 48 h study period. Owing to its ultra small 
size and high lipophilic nature, CNLV-2 showed preferential 
internalization in U87MG human glioblastoma cells. MTT assay 
showed a higher toxicity of CNL-2 on the tested cancer cells than 
free CS. The formulation showed improved PK profile in 
experimental mice models than free drug. Significant increase in 
important PK parameters like AUC and MRT for CNLV-2 justified its 
higher bioavailability and in vivo stability. Future plan of work 
includes testing of the optimized CNLV-2 in brain tumor bearing 
xenograft models to gather data for future clinical applications.  
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